Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.00682352941176469 0.00682352941176469
Stock impact report

Impax Labs +4% as FDA approves generic Renvela [Seeking Alpha]

IMPAX LABORATORIES (IPXL) 
Last impax laboratories earnings: 3/1 07:00 am Check Earnings Report
Company Research Source: Seeking Alpha
Impax Labs +4% as FDA approves generic RenvelaImpax Laboratories (NASDAQ:IPXL)+3.9% after-hours on news that theFDA approved its generic version of Sanofi's (NYSE:SNY) Renvela sevelamer carbonate tablets.IPXL says it has immediately started commercialization of the product; sales of Renvela are reflected in the company's previously issued FY 2017 EPS guidance of $0.55-$0.70.U.S. sales of sevelamer carbonate tablets totaled $1.9B for the 12 months ending August 2017.See all stocks on the move » Show less Read more
Impact Snapshot
Event Time:
IPXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IPXL alerts
Opt-in for
IPXL alerts

from News Quantified
Opt-in for
IPXL alerts

from News Quantified